RESUMO
This study presents a theoretical framework for defining the performance level of wireless safety functions within industrial environments. While acknowledging the simplifications inherent in our approach-primarily based on packet loss rates as a measure of system performance-the study underscores the dynamic challenges posed by real-world warehouses. Through an in situ measurement study of a forklift truck safety system, we validate the proposed method and emphasize the need for a more nuanced examination of wireless communication in complex settings. The study advocates for an expanded theoretical framework that considers fluctuations in warehouse dynamics, accounting for their impact on packet loss rates and, consequently, the precision of performance-level assessments. Furthermore, the research highlights the complexity introduced by wireless system characteristics not addressed in the simplified model, urging future investigations to incorporate these factors for a comprehensive understanding of wireless safety systems. The absence of specific criteria for wireless systems within existing standards emphasizes the necessity for a specialized framework in addressing safety aspects unique to wireless applications.
RESUMO
Pemetrexed is a structurally novel antifolate agent approved in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma who have unresectable disease and for the therapy of previously treated patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) as a single agent or in association with cisplatin as a first-line treatment in patients with nonsquamous histology. Herein, we report a case of pemetrexed-induced pneumonitis. Because pemetrexed is being prescribed with increasing frequency for NSCLC and mesothelioma, we believe that physicians should be aware of this rare but serious complication.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Hipersensibilidade a Drogas/diagnóstico , Neoplasias Pulmonares/tratamento farmacológico , Pulmão/efeitos dos fármacos , Pneumonia/diagnóstico , Nódulo Pulmonar Solitário/tratamento farmacológico , Corticosteroides/administração & dosagem , Idoso , Anti-Infecciosos/administração & dosagem , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/fisiopatologia , Ciprofloxacina/administração & dosagem , Cisplatino/administração & dosagem , Cisplatino/efeitos adversos , Hipersensibilidade a Drogas/patologia , Hipersensibilidade a Drogas/fisiopatologia , Quimioterapia Combinada , Dispneia , Eritema , Glutamatos/administração & dosagem , Glutamatos/efeitos adversos , Guanina/administração & dosagem , Guanina/efeitos adversos , Guanina/análogos & derivados , Humanos , Pulmão/metabolismo , Pulmão/patologia , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/fisiopatologia , Masculino , Recidiva Local de Neoplasia , Paclitaxel/administração & dosagem , Pemetrexede , Pneumonia/induzido quimicamente , Pneumonia/patologia , Pneumonia/fisiopatologia , Fibrose Pulmonar , Recuperação de Função Fisiológica , Nódulo Pulmonar Solitário/diagnóstico , Nódulo Pulmonar Solitário/patologia , Nódulo Pulmonar Solitário/fisiopatologiaRESUMO
Hypertension, proteinuria, thromboembolic or bleeding events are well-recognized complications occurring while targeting VEGF pathway. Wound healing dysfunctions have also been described in patients undergoing major surgery. For the first time, we report wound healing delay after central venous access following DCF-VEGF-Trap. VEGF-Trap may affect both angiogenesis and reepithelialization which are necessary to the normal repair process.
